Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 69.53

-1.0%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2509)	6/12/2009 9:02:09 AM
From: Jibacoa	Read Replies (2) of 3722

SVNT is up 45.03% in pre-maket trading.<g> The stock is trading at $8.65 above its January H. :>) bigcharts.marketwatch.com It announced on 5/7/09 that its pending BLA for Krystexxa for treatment of gout patients, will be reviewed by an Arthritis Advisory Committee of the FDA on 6/16/09. Back in December, the FDA accepted the BLA and granted priority review status. However,after SVNT submitted several key amendments for the BLA in January,the FDA determined that the additional information constituted a major amendment and had extended the original action date to 8/1/09. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next